Business Context and Reporting Period
This Form 8-K Current Report was filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on April 14, 2020, with the earliest event reported on that date. The filing details a registered direct offering of common stock that closed on April 15, 2020.
Key Financial Metrics
- Gross Proceeds: Approximately $14.0 million from the sale of 14,000,000 shares.
- Offering Price: $1.00 per share.
- Placement Agent Fees:
- Cash fee: 8.0% of gross proceeds.
- Management fee: $140,000 (1.0% of gross proceeds).
- Non-accountable expense allowance: $65,000.
- Clearing fee: $12,900.
- Warrant Issuance: 1,120,000 warrants issued to the placement agent (8.0% of shares sold) with an exercise price of $1.25 per share and a five-year term.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the increase in equity capital through the issuance of 14,000,000 new shares of common stock. The company also entered into a Securities Purchase Agreement containing customary restrictions on the issuance of additional common stock or equivalents for a 30-day period following the closing.
Guidance, Outlook, and Risks
- Management Commentary: The filing focuses on the mechanics of the capital raise and does not provide specific operational guidance or future earnings outlook.
- Contingencies: The company agreed to pay a "tail fee" to the placement agent equal to the cash and warrant compensation if purchasers introduced by the agent provide capital within 12 months of the engagement's termination.
- Risks: The offering was subject to market conditions and negotiations. The placement agent's warrants were issued unregistered under Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the exact net proceeds after deducting all placement agent fees and offering expenses.
- Confirm the dilution impact of the 14,000,000 new shares and the 1,120,000 placement agent warrants on existing shareholders.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and the 30-day lock-up restrictions.
- Check the company's cash position post-offering to assess runway for operations, as this filing does not disclose current liquidity.